TWi Biotechnology, Inc. (TPEX:6610)

Market Cap	3.95B
Revenue (ttm)	n/a
Net Income (ttm)	-155.28M
Shares Out	107.63M
EPS (ttm)	-1.77
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,222,388
Average Volume	1,482,571
Open	33.15
Previous Close	32.85
Day's Range	32.60 - 38.55
52-Week Range	8.96 - 38.55
Beta	0.19
RSI	76.01
Earnings Date	Nov 13, 2025

About TWi Biotechnology

TWi Biotechnology, Inc., a clinical-stage biopharmaceutical company, develops and sells drugs for innate immunity-related diseases in Taiwan. The company development pipeline comprises AC-203, which is in Phase 2 clinical trial for various indications, including epidermolysis bullosa simplex, epidermolysis bullosa, arthritis, gout, and diabetes mellitus; and AC- 1101, which is in Phase 1 trial for the treatment of vitiligo and preclinical stage for the treatment of atopic dermatitis, as well as granuloma annulare and rare autoimmune skin diseas...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 23
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6610